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It has been shown that HIV-1 infects activated but not
resting CD4+ T cells [1] and that CPE induced by viral
replication together with the immunosuppressive effect
triggered by extracellular Tat protein [2] account for the
decrease of CD4+ T cell count in infected patients. In
lymphoid foci, dependent on the level of viral infection,
the stromal microenvironment surrounding immune
cells could include, together with extracellular Tat [3]
and circulating antiviral IFN-a, inflammatory innate fac-
tors such as ATP and derivatives released by CPE-
derived dead cells.
We show that, according to its concentration and the
presence of inflammatory factors (IFN-a, ATP and
ATP-derivatives), Tat protein may exert either an activa-
tion with enhanced production of IL2 or an immune
suppression of stimulated CD4+ T cells subpopulations.
The double-edged sword of Tat activity on CD4+ T
cells could account for its immunopathogenic effects
both at the early stage of infection (by allowing CD4+ T
cells activation and viral replication) and at late stages
(by inducing immuosuppression, source of opportunistic
infections). Indications for targeting Tat protein by ther-
apeutic vaccines in subgroups of HIV-1 infected patients
will be discussed.
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